---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-033475"
form_type: "8-K"
ticker: "DSGN"
cik: "0001807120"
company_name: "Design Therapeutics, Inc."
filed_at: "2024-03-19T23:59:59+00:00"
generated_at: "2026-06-04T13:39:43.576623+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Design Therapeutics reports $281.8M cash, new FA drug product DT-216P2, IND cleared for DT-168, new HD program

## Summary
- Net loss $11.8M in Q4 2023 and $66.9M for full year; cash & securities $281.8M funding 5-year runway.
- New FA drug product DT-216P2 shows >10-fold improved PK and favorable injection site safety; GLP studies to complete by year-end 2024 for patient trials in 2025.
- FDA cleared IND for DT-168 in FECD; Phase 1 to start in 2024; observational study of 200 patients underway.
- New HD program targeting mutant HTT shows >50% selective reduction in brain striatum in preclinical studies.
- DM1 GeneTAC molecules potently dial-down mutant DMPK, restore splicing; working toward development candidate.

## SEC filing metadata
- accession: 0000950170-24-033475
- form_type: 8-K
- ticker: DSGN
- cik: 0001807120
- company_name: Design Therapeutics, Inc.
- filed_at: 2024-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1807120/000095017024033475/0000950170-24-033475-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1807120/000095017024033475/dsgn-20240319.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-033475
- JSON: https://secwatch.observer/filing/0000950170-24-033475.json
- Plain text: https://secwatch.observer/filing/0000950170-24-033475.txt

## Key facts
- Earnings Releases
  Design Therapeutics, Inc. reported financial results for the three and twelve months ended December 31, 2023.
  - Period: the three and twelve months ended December 31, 2023
  - Result: reported results
  source text: On March 19, 2024, Design Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1807120/000095017024033475/0000950170-24-033475-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.